[ad_1]
Agilent Technologies has recently introduced the NovoCyte Opteon Spectral Flow Cytometer, the latest addition to its flow cytometry platform. With the ability to analyze over 40 markers simultaneously, this new technology enables researchers to conduct large-panel flow cytometry assays and undertake sophisticated cell analysis research. Xiaobo Wang, the vice president and general manager of Agilent’s Cell Function and Phenotyping Business, recently discussed some of the advanced spectral capabilities of the NovoCyte Opteon and how they address challenges in flow cytometry.
Since the launch of the NovoCyte flow cytometry platform in 2014, Agilent has made significant strides in developing new generation NovoCyte cytometers with enhanced detection sensitivity. The NovoCyte line now includes models with up to 30 fluorescent channels and advanced software for improved productivity and compliance.
The NovoCyte Opteon was designed to meet the growing demand for spectral flow cytometers in the cell analysis market. Its innovative technology allows for better differentiation and detection of fluorochromes and improved resolution of low-expressing targets. The integrated analytical software, NovoExpress, offers users a simple and intuitive workflow for running experiments and analyzing data.
The NovoCyte Opteon is expected to benefit a wide range of research applications, particularly in immunology and cell therapy development. With its ability to handle large flow assay panels and provide better sensitivity for low-expression biomarkers, the NovoCyte Opteon is poised to advance scientific research and therapeutic development. Overall, this new product represents a milestone in democratizing flow cytometry assays and is expected to contribute significantly to the future of this technology.
Source
Photo credit www.technologynetworks.com